ClinicalTrials.gg

Program

F8IL10

Its studies are mostly in Arthritis, Rheumatoid, led by Philogen.

Furthest: phase 2, since Oct 16, 20144 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen41 open or runningphase 2since Oct 16, 2014Feb 24, 2014Sep 30, 2028phase 1 · NCT07245992

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2014First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT02076659 · 36 enrolled · Italy
  2. Oct 16, 2014Phase 2 study in Arthritis, RheumatoidNCT02270632 · 27 enrolled · Germany, Italy, Switzerland
  3. Nov 3, 2022Phase 1 study in Arthritis, RheumatoidNCT05622175
  4. Aug 19, 2025Phase 1 study in Arthritis, RheumatoidNCT07245992 · 54 planned · Italy

Ahead

  1. Sep 30, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07245992

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07245992Arthritis, Rheumatoid · Italy1RecruitingSep 30, 202854
NCT05622175Arthritis, Rheumatoid1WithdrawnDec 31, 20250
NCT02270632Arthritis, Rheumatoid · Germany, Italy, Switzerland2TerminatedApr 201927
NCT02076659Arthritis, Rheumatoid · Italy1CompletedApr 201736

How it is read

Names in the registry

  • “F8IL10”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.